Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biofrontera Inc. Warrants (BFRIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/27/2025: BFRIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.08% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.3 | 52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 |
52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.33% | Operating Margin (TTM) -52.95% |
Management Effectiveness
Return on Assets (TTM) -49.47% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 7102407 |
Shares Outstanding - | Shares Floating 7102407 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biofrontera Inc. Warrants
Company Overview
History and Background
Biofrontera Inc. is a biopharmaceutical company specializing in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Biofrontera AG (B8F:GR), the parent company, was founded in 1997. Biofrontera Inc. Warrants represents rights to purchase shares of the parent company's stock.
Core Business Areas
- Dermatology Products: Development and commercialization of prescription drugs and medical devices for the treatment of skin diseases.
Leadership and Structure
Biofrontera Inc. Warrants derive their value from the underlying equity of Biofrontera AG. Leadership structure will depend on the Warrant's terms and relation to the main company of Biofrontera AG.
Top Products and Market Share
Key Offerings
- Warrants: Represent the right to purchase shares of Biofrontera AG at a specific price and date. Market share is not applicable to Warrants as they are derivative financial instruments. Competitors are other pharmaceutical company warrants
Market Dynamics
Industry Overview
The biopharmaceutical industry is driven by innovation in drug development and treatments for unmet medical needs. Regulatory approvals and market access play crucial roles.
Positioning
Biofrontera Inc. Warrants's positioning depends on the underlying share price of Biofrontera AG and market perception. Warrants allow higher leverage to the stock movement.
Total Addressable Market (TAM)
TAM is linked to the underlying value of Biofrontera AG shares. Warrant positioning within TAM depends on leverage factor.
Upturn SWOT Analysis
Strengths
- Potential for high leverage gains if Biofrontera AG's stock price increases
- Relatively lower initial investment compared to purchasing shares directly
Weaknesses
- Warrants expire and can become worthless if the stock price doesn't reach the strike price
- High volatility and risk associated with derivative instruments
Opportunities
- Positive clinical trial results for Biofrontera AG's products
- Market expansion and increased adoption of Biofrontera AG's treatments
Threats
- Regulatory setbacks or delays in drug approvals for Biofrontera AG
- Competition from other pharmaceutical companies
Competitors and Market Share
Key Competitors
- Other biopharmaceutical stock options and warrants
Competitive Landscape
Biofrontera Inc. Warrants's value is linked to Biofrontera AG's position in the biopharmaceutical market.
Growth Trajectory and Initiatives
Historical Growth: Warrant value is derived from Biofrontera AG's growth.
Future Projections: Future warrant value projections depend on Biofrontera AG's performance and investor sentiment.
Recent Initiatives: The value is derived from the underlying asset.
Summary
Biofrontera Inc. Warrants offer leveraged exposure to Biofrontera AG's stock performance. The warrants are a high-risk, high-reward investment. Factors like Biofrontera AG's success in drug development, regulatory approvals, and market competition play crucial roles. Investors must carefully assess the terms of the warrants and the financial health of Biofrontera AG before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings of Biofrontera AG
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in warrants involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc. Warrants
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.